Dr. Liu is a founding partner of 3E Bioventures Capital, a healthcare-focused venture capital firm. Prior to 3E Bioventures, she was a partner at Kaiwu Capital, in charge of healthcare investment, and was managing director at CRCI Capital, also in charge of healthcare investment. She is a co-founder and investor of Shenogen Pharma, a company developing innovative liver cancer therapeutics, and was an entrepreneur and senior team member of 3721, an internet-search company that was sold to Yahoo in early 2004. Earlier, Dr. Liu was a consultant at McKinsey & Company. Dr. Liu has been active in China healthcare venture investment since 2006, with investments in device, diagnostics and drug companies. Increasingly, she invests in the cross-sector innovations between medtech and information technology. Dr. Liu earned a B.S. from Cornell University, Master of Medical Sciences degree from Harvard University and a Ph.D. in Immunology from Harvard University. She also received an EMBA degree from the Chungkong Graduate School of Business in China.